EUVIMEDEUVIMED entdecken
Crossref

Two‐Decade Trends in MASLD and Its Complications in the Middle East and North Africa (2010–2021)

Zobair M Younossi iD, James M Paik, Yusuf Yilmaz iD, Mustafa Kanat, Mohamed El-Kassas iD, Said A Al-Busafi iD, Khalid M Al-Naamani iD, Abdel-Naser Elzouki iD, Khalid Alswat iD, Ahmed Cordie, Ashraf Omar Abdelaziz Osman iD, Nabil Debzi und 9 weitere

Liver International · 2025

DOI: 10.1111/liv.70342 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Liver International, 2025. Verfasst von Zobair M Younossi und 20 weiteren Autor:innen. Beteiligte Einrichtung: The Global NASH Council, Washington, DC, USA. Hauptthemen laut MEDLINE: Liver Cirrhosis, Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 18 Literaturangaben. Gefördert von: The Global NASH Council, The Center for Outcomes Research in Liver Disease, Beatty Liver and Obesity Research Program, Inova Health System.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The Middle East and North Africa (MENA) region is undergoing demographic shifts potentially increasing metabolic dysfunction‐associated steatotic liver disease (MASLD) and its complications. We assessed MASLD prevalence and liver disease burden from 2010 to 2021.

Methods

Data from Global Burden of Disease (GBD), United Nations Population Division and NCD Risk Factor Collaboration covering 21 MENA countries were used for annual percent change (APC) trends per Joinpoint regression. Regression modelling determined MASLD cirrhosis prevalence (compensated [CC]/decompensated cirrhosis [DCC]). Prevalence and mortality estimates were age‐standardised (children and adults).

Results

MENA region's population: progressively aged, increased (518–623 million), and experienced prevalence increases in adult diabetes (7.4%–12.1%), obesity (25.4%–31.3%) and MASLD (26.3% [117.97 million] to 27.7% [164.31 million]; APC = 0.47%; 95% CI, 0.35–0.59); steeper increase in adults ≥ 20 years (37.1%–41.0%; APC = 0.90%; 0.79–1.01). MASLD cirrhosis (0.22% [1.13 million] to 0.28% [1.73 million]; APC = 2.18%; 2.05–2.31), CC (0.20%–0.25%; APC = 2.24%) and DCC (0.020%–0.025%; APC = 2.23%) increased. Algeria, Iraq, Morocco and Turkey had the highest increases (APCs > 2.8% for both CC and DCC). MASH cirrhosis mortality (APC = 0.60%), and DALYs (APC = 0.47%) increased. MASH liver cancer prevalence (APC = 2.90%), incidence (APC = 2.90%), mortality (0.50–0.69 per 100 000; APC = 2.87%) and DALYs (APC = 2.51%) increased. Iran had the most rapid increases (APC > 6%) for all liver cancer outcomes; Egypt accounted for ≥ 50% liver cancer DALYs in 2021. Kuwait, West‐Bank/Gaza and United Arab Emirates showed stable/declining trends.

Conclusions

The prevalence of MASLD and associated complications (cirrhosis and liver cancer) increased substantially across the MENA region from 2010 to 2021, with variation across countries.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver CirrhosisNon-alcoholic Fatty Liver DiseaseHumansAfrica, NorthernMiddle EastPrevalenceAdultFemaleMaleMiddle AgedAgedYoung AdultChildAdolescentRisk FactorsGlobal Burden of Disease

Autor:innen und Institutionen

  • The Global NASH Council, Washington, DC, USA.
  • Beatty Liver and Obesity Research Program, Inova Health System, Falls Church, Virginia, USA.
  • Department of Gastroenterology, School of Medicine, Recep Tayyip Erdoğan University, Istanbul, Turkey.
  • Department of Medicine, DIMER Diabetes Research Center, Istanbul Medeniyet University, Istanbul, Turkey.
  • Endemic Medicine Department, Faculty of Medicine, Helwan University, Cairo, Egypt.
  • Gastroenterology and Hepatology Unit, Department of Medicine, College of Medicine and Health Sciences, Sultan Qaboos University, Muscat, Oman.

ORCID-Profile: Zobair M Younossi, Yusuf Yilmaz, Mohamed El-Kassas, Said A Al-Busafi, Khalid M Al-Naamani, Abdel-Naser Elzouki, Khalid Alswat, Ashraf Omar Abdelaziz Osman, Linda Henry, Shira Zelber-Sagi

Förderung

  • The Global NASH Council
  • The Center for Outcomes Research in Liver Disease
  • Beatty Liver and Obesity Research Program, Inova Health System

Zitieren

APA

Younossi, Z. M., Paik, J. M., Yilmaz, Y., Kanat, M., El-Kassas, M., Al-Busafi, S. A., Al-Naamani, K. M., Elzouki, A. N., Alswat, K., Cordie, A., Osman, A. O. A., Debzi, N., Khamis, J., Hassanein, M., Abu-Farha, M., Al-Mulla, F., Aba-Alkhail, F., Henry, L., Zelber-Sagi, S., …, & AlQahtani, S. (2025). Two‐Decade Trends in MASLD and Its Complications in the Middle East and North Africa (2010–2021). Liver International. https://doi.org/10.1111/liv.70342

Vancouver

Younossi ZM, Paik JM, Yilmaz Y, Kanat M, El-Kassas M, Al-Busafi SA, et al. Two‐Decade Trends in MASLD and Its Complications in the Middle East and North Africa (2010–2021). Liver International. 2025. doi:10.1111/liv.70342

BibTeX
@article{Younossi2025,
  author = {Younossi, Zobair M and Paik, James M and Yilmaz, Yusuf and Kanat, Mustafa and El-Kassas, Mohamed and Al-Busafi, Said A and Al-Naamani, Khalid M and Elzouki, Abdel-Naser and Alswat, Khalid and Cordie, Ahmed and Osman, Ashraf Omar Abdelaziz and Debzi, Nabil and Khamis, Jawad and Hassanein, Mohamad and Abu-Farha, Mohamed and Al-Mulla, Fahd and Aba-Alkhail, Faisal and Henry, Linda and Zelber-Sagi, Shira and Alaklabi, Asrar and AlQahtani, Saleh},
  title = {Two‐Decade Trends in MASLD and Its Complications in the Middle East and North Africa (2010–2021)},
  journal = {Liver International},
  year = {2025},
  doi = {10.1111/liv.70342}
}
Kostenlos starten →